Vasculitis Treatment Market Expected to Reach $350.1 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Vasculitis Treatment Market," The vasculitis treatment market was valued at $250.09 million in 2021, and is estimated to reach $350.1 million by 2031, growing at a CAGR of 3.4% from 2022 to 2031.

Vasculitis is a disease in which blood arteries become inflamed and affect the skin, eyes, brain, or other internal organs. Fatigue, weakness, weight loss, muscle discomfort, congestive heart failure, malaise, and other symptoms are among the related symptoms that have been noticed. Numerous pharmaceuticals, including cytotoxic drugs, immunosuppressants, and corticosteroids, are used as treatment methods.

Although the exact cause of vasculitis is unknown, there are a number of things that can cause it, including a person's genetic make-up, blood malignancies, immune system disorders such as rheumatoid arthritis, infections such as hepatitis B, and drug reactions. Blood artery inflammation can result in a number of adverse effects. It might obstruct blood flow, which would make organs dysfunctional.

Increase in the elderly population group, which is more prone to vasculitis, is the major driver of this market. In addition, rise in incidence of chronic diseases that can lead to vasculitis is the vasculitis treatment market trends. Furthermore, surge in use of corticosteroids and immunosuppressants is expected to boost the vasculitis treatment market forecast.

However, side effects associated with use of corticosteroids is expected to hinder the market growth. Conversely, increase in R&D activities for drug development and discovery is a great opportunity for key players to invest during the forecast period especially in the developing economies.

The vasculitis treatment market analysis is classified on the basis of drug class, disease type, distribution channel, and region. By drug class, the market is segmented into biologics and corticosteroids & immunosuppressants. The corticosteroids & immunosuppressants segment dominated the vasculitis treatment market size in 2021, owing to increase in demand for corticosteroids due to their cost effectiveness and rise in demand for immunosuppressants owing to their efficacy. The biologics segment is expected to witness the highest CAGR during the forecast period not only due to side effects associated with usage of corticosteroids but also due to the development of various biologics.

Depending on disease type, the market is divided into small & medium vessel vasculitis, and large vessel vasculitis. The small & medium vessel vasculitis segment dominated the vasculitis treatment market size in 2021, and is expected to witness highest CAGR during the forecast period owing to higher incidence of vasculitis diseases as well as the availability of treatment for them.

Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the vasculitis treatment market share in 2021, owing to availability of all medications used in hospitals and the reimbursement policies in developing countries for vasculitis medications. The drug store & retail pharmacies segment is expected to witness highest CAGR during the forecast period owing to maintenance of treatment for a long duration and easy availability of drugs. 

North America accounted for a majority of the global vasculitis treatment market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in vasculitis treatment, and presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in geriatric population, development of healthcare infrastructure, and increase in investments projects in the region.

Key findings of the study
•    By drug class, the corticosteroids & immunosuppressants segment was the highest contributor to the vasculitis treatment industry in 2021.
•    By disease type, the small and medium vessel vasculitis segment was the highest contributor to the vasculitis treatment industry in 2021.
•    Depending on distribution channel, the hospital pharmacies segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.
•    Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.